Form 4: Pliant Therapeutics Director Katharine Knobil Granted 30,000 Stock Options

Pliant Therapeutics, Inc. director Katharine Knobil was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Katharine Knobil, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 stock options to acquire Common Stock.
• The options have an exercise price of $1.61 per share.
• The grant date for these options was June 5, 2025, and they expire on June 5, 2035.
• The vesting schedule is structured with 25% of the shares vesting on October 1, 2025, January 1, 2026, and April 1, 2026, respectively.
• The final 25% of the shares will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the next annual meeting of stockholders.
• Vesting is contingent upon Ms. Knobil's continued service as a Director of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event for a director, aligning interests, but doesn't indicate significant operational news or financial performance.

Positives

• The grant of 30,000 stock options aligns the director's interests with long-term shareholder value, as the options become more valuable with an increase in the company's stock price.
• The vesting schedule encourages continued service and commitment from a key board member.

Negatives

• No direct negatives are apparent from this routine stock option grant to a director.

Risks

• The vesting of the options is subject to the reporting person's continued service to the Issuer as a Director, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing (Form 4) for a director's equity compensation, which is common practice across the biotechnology and pharmaceutical industries to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The remaining 25% of the options will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Pliant Therapeutics, PLRX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Katharine Knobil